<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="pt" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq Bras Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40136155</article-id><article-id pub-id-type="pmc">PMC12017458</article-id><article-id pub-id-type="other">00502</article-id><article-id pub-id-type="doi">10.36660/abc.20240535</article-id><article-categories><subj-group subj-group-type="heading"><subject>Carta Cient&#x000ed;fica</subject></subj-group></article-categories><title-group><article-title>Doen&#x000e7;a de Fabry e seus Diferentes Fen&#x000f3;tipos</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8071-924X</contrib-id><name><surname>Antunes</surname><given-names>Murillo Oliveira</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-0241-5535</contrib-id><name><surname>Nastari</surname><given-names>Rafael Ruas</given-names></name><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arteaga-Fernandez</surname><given-names>Edmundo</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-1246-4838</contrib-id><name><surname>Lizandro</surname><given-names>Marcelle G. Henriques</given-names></name><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>El-Feghaly</surname><given-names>William Batah</given-names></name><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Guilherme Jos&#x000e9; dos Santos</given-names></name><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Alan Silva</given-names></name><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leguizamon</surname><given-names>Juliana Alzira Gonzales Oliveira</given-names></name><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Correia</surname><given-names>Vinicius Machado</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><role>Revis&#x000e3;o cr&#x000ed;tica do manuscrito quanto ao conte&#x000fa;do</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Madrini</surname><given-names>Vagner</given-names><suffix>Junior</suffix></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><role>An&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos dados</role><role>Reda&#x000e7;&#x000e3;o do manuscrito</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9323-8805</contrib-id><name><surname>Fernandes</surname><given-names>F&#x000e1;bio</given-names></name><role>Concep&#x000e7;&#x000e3;o e desenho da pesquisa</role><role>Obten&#x000e7;&#x000e3;o de dados</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="orgdiv2">Hospital das Cl&#x000ed;nicas</institution>
<institution content-type="orgdiv1">Faculdade de Medicina</institution>
<institution content-type="orgname">Universidade de S&#x000e3;o Paulo</institution>
<addr-line>
<named-content content-type="city">S&#x000e3;o Paulo</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Instituto do Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP &#x02013; Brasil</institution>
</aff><aff id="aff2">
<label>2</label>
<institution content-type="orgname">Universidade S&#x000e3;o Francisco</institution>
<addr-line>
<named-content content-type="city">Bragan&#x000e7;a Paulista</named-content>
<named-content content-type="state">SP</named-content>
</addr-line>
<country country="BR">Brasil</country>
<institution content-type="original">Universidade S&#x000e3;o Francisco, Bragan&#x000e7;a Paulista, SP &#x02013; Brasil</institution>
</aff><author-notes><corresp id="c01">
<label>Correspond&#x000ea;ncia</label>
<bold>: Rafael Ruas Nastari</bold>
&#x02022; Rua Doutor Diogo de Faria, 1077, apto. 62. CEP 04037-003, S&#x000e3;o Paulo, SP &#x02013; Brasil E-mail:
<email>rafael_nastari@msn.com</email>
</corresp><fn fn-type="COI-statement"><p><bold>Potencial conflito de interesse:</bold> N&#x000e3;o h&#x000e1; conflito com o presente artigo.</p></fn><fn fn-type="edited-by"><p><bold>Editor respons&#x000e1;vel pela revis&#x000e3;o:</bold> Nat&#x000e1;lia Olivetti</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>122</volume><issue>2</issue><elocation-id>e20240535</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>01</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Este &#x000e9; um artigo de acesso aberto distribu&#x000ed;do sob os termos da licen&#x000e7;a de atribui&#x000e7;&#x000e3;o pelo Creative Commons</license-p></license></permissions><abstract><title>Resumo</title><p>A Doen&#x000e7;a de Fabry (DF) &#x000e9; uma condi&#x000e7;&#x000e3;o gen&#x000e9;tica ligada ao cromossomo X, causada por variantes no gene
<italic toggle="yes">GLA</italic>
, que resultam na defici&#x000ea;ncia da enzima &#x003b1;-galactosidase A e no ac&#x000fa;mulo de globotriaosilceramida (Gb3) em tecidos como o cora&#x000e7;&#x000e3;o, rins e sistema nervoso. Este estudo relata uma s&#x000e9;rie de casos envolvendo pacientes diagnosticados com DF, destacando a diversidade fenot&#x000ed;pica da doen&#x000e7;a, que pode ser confundida com outras condi&#x000e7;&#x000f5;es cardiol&#x000f3;gicas. A avalia&#x000e7;&#x000e3;o gen&#x000e9;tica, aliada &#x000e0; dosagem de biomarcadores e &#x000e0; atividade enzim&#x000e1;tica da &#x003b1;-galactosidase, quando bem indicadas, &#x000e9; essencial para o diagn&#x000f3;stico preciso. O diagn&#x000f3;stico precoce da DF &#x000e9; fundamental para a implementa&#x000e7;&#x000e3;o de tratamentos que retardem a sua progress&#x000e3;o, al&#x000e9;m de evitar complica&#x000e7;&#x000f5;es graves, refor&#x000e7;ando a necessidade de maior conscientiza&#x000e7;&#x000e3;o entre os cardiologistas sobre essa condi&#x000e7;&#x000e3;o.</p></abstract><kwd-group><kwd>Doen&#x000e7;a de Fabry</kwd><kwd>Cardiomiopatias</kwd><kwd>Gen&#x000e9;tica</kwd></kwd-group><counts><fig-count count="4"/><table-count count="4"/><equation-count count="0"/><ref-count count="9"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introdu&#x000e7;&#x000e3;o</title><p>A Doen&#x000e7;a de Fabry (DF) &#x000e9; uma desordem lisoss&#x000f4;mica de armazenamento ligada ao cromossomo X, causada por variantes patog&#x000ea;nicas no gene
<italic toggle="yes">GLA</italic>
, que resultam em uma redu&#x000e7;&#x000e3;o significativa da atividade da enzima &#x003b1;-galactosidase A (&#x003b1;-GalA). Isso leva ao ac&#x000fa;mulo de globotriaosilceramida (Gb3) em tecidos como cora&#x000e7;&#x000e3;o, rins, vasos sangu&#x000ed;neos e sistema nervoso perif&#x000e9;rico. Embora as estimativas de incid&#x000ea;ncia variem, estudos recentes, incluindo triagens neonatais e an&#x000e1;lises de biobanco sugerem que a preval&#x000ea;ncia real pode ser subestimada, com acometimento de at&#x000e9; 1 em 5.732 para variantes de in&#x000ed;cio tardio.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup> Com a introdu&#x000e7;&#x000e3;o da terapia de reposi&#x000e7;&#x000e3;o enzim&#x000e1;tica (TRE), o diagn&#x000f3;stico precoce tornou-se crucial para retardar a progress&#x000e3;o da doen&#x000e7;a. Esta s&#x000e9;rie de casos visa demonstrar as diferentes apresenta&#x000e7;&#x000f5;es fenot&#x000ed;picas da DF, que podem mimetizar outras cardiopatias, facilitando assim o reconhecimento precoce da condi&#x000e7;&#x000e3;o.</p><sec><title>Caso 01 &#x02013; Cardiomiopatia hipertr&#x000f3;fica apical</title><p>Paciente masculino, 29 anos, sem comorbidades ou hist&#x000f3;ria familiar de cardiopatia, queixava-se de formigamento e queima&#x000e7;&#x000e3;o nas pernas, assim como uma mancha em regi&#x000e3;o abdominal (angioqueratomas). Procurou um servi&#x000e7;o de sa&#x000fa;de devido precordialgia at&#x000ed;pica (
<xref rid="t1" ref-type="table">Tabela 1</xref>
). O eletrocardiograma (ECG) mostrou intervalo PR curto e sinais de sobrecarga ventricular esquerda (SVE) com invers&#x000e3;o de ondas T em V3-V6 (
<xref rid="f01" ref-type="fig">Figura 1</xref>
). O ecocardiograma revelou hipertrofia assim&#x000e9;trica do ventr&#x000ed;culo esquerdo (VE) na regi&#x000e3;o apical, com espessura m&#x000e1;xima de 17 mm e aus&#x000ea;ncia de obstru&#x000e7;&#x000e3;o na via de sa&#x000ed;da do VE, sendo inicialmente diagnosticado com cardiomiopatia hipertr&#x000f3;fica (CMH) n&#x000e3;o obstrutiva, forma apical. A resson&#x000e2;ncia magn&#x000e9;tica card&#x000ed;aca (RMC) evidenciou hipertrofia circunferencial nos segmentos m&#x000e9;dios e apicais, com espessura de 21 mm e realce tardio mioc&#x000e1;rdico multifocal de padr&#x000e3;o n&#x000e3;o isqu&#x000ea;mico (
<xref rid="f01" ref-type="fig">Figura 1</xref>
). A investiga&#x000e7;&#x000e3;o gen&#x000e9;tica revelou uma variante patog&#x000ea;nica no gene
<italic toggle="yes">GLA</italic>
(
<xref rid="t2" ref-type="table">Tabela 2</xref>
), e a dosagem da enzima alfa-galactosidase mostrou valor reduzido, confirmando o diagn&#x000f3;stico de DF. Foi realizado um rastreio familiar e encontrado a mesma variante na m&#x000e3;e do paciente.</p><p>
<table-wrap position="float" id="t1"><label>Tabela 1</label><caption><title>&#x02013; Caracter&#x000ed;sticas cl&#x000ed;nico-laboratoriais</title></caption><table frame="hsides" rules="groups"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Caso #1</th><th rowspan="1" colspan="1">Caso #2</th><th rowspan="1" colspan="1">Caso #3</th><th rowspan="1" colspan="1">Caso #4</th><th rowspan="1" colspan="1">Caso #5</th><th rowspan="1" colspan="1">Caso #6</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Idade, anos</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td rowspan="1" colspan="1">Sexo</td><td align="center" rowspan="1" colspan="1">Masculino</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Masculino</td><td align="center" rowspan="1" colspan="1">Feminino</td><td align="center" rowspan="1" colspan="1">Masculino</td></tr><tr><td rowspan="1" colspan="1">Fen&#x000f3;tipo</td><td align="center" rowspan="1" colspan="1">CMH apical</td><td align="center" rowspan="1" colspan="1">Amiloidose card&#x000ed;aca</td><td align="center" rowspan="1" colspan="1">Fibrila&#x000e7;&#x000e3;o atrial</td><td align="center" rowspan="1" colspan="1">Assintom&#x000e1;tico</td><td align="center" rowspan="1" colspan="1">(Insufici&#x000ea;ncia Card&#x000ed;aca com Fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o preservada) ICFEp</td><td align="center" rowspan="1" colspan="1">(Insufici&#x000ea;ncia Card&#x000ed;aca com Fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o reduzida) ICFEr</td></tr><tr><td rowspan="1" colspan="1">Apresenta&#x000e7;&#x000e3;o cl&#x000ed;nica</td><td align="center" rowspan="1" colspan="1">Sintomas cardiovasculares &#x02013; Dor precordial</td><td align="center" rowspan="1" colspan="1">Hipoidrose, Acroparestesia e palpita&#x000e7;&#x000f5;es</td><td align="center" rowspan="1" colspan="1">Palpita&#x000e7;&#x000f5;es, Acroparestesia e vertigem</td><td align="center" rowspan="1" colspan="1">Anidrose e intoler&#x000e2;ncia ao calor</td><td align="center" rowspan="1" colspan="1">Sintomas cardiovasculares &#x02013; Dispneia</td><td align="center" rowspan="1" colspan="1">Sintomas cardiovasculares &#x02013; Dispneia</td></tr><tr><td rowspan="1" colspan="1">Intervalo PR curto</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td rowspan="1" colspan="1">FEVE, %</td><td align="center" rowspan="1" colspan="1">Preservada</td><td align="center" rowspan="1" colspan="1">Preservada</td><td align="center" rowspan="1" colspan="1">Preservada</td><td align="center" rowspan="1" colspan="1">Preservada</td><td align="center" rowspan="1" colspan="1">Preservada</td><td align="center" rowspan="1" colspan="1">Reduzida</td></tr><tr><td rowspan="1" colspan="1">Espessura m&#x000e1;xima, mm</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td rowspan="1" colspan="1">Dosagem de &#x003b1;-galactosidase</td><td align="center" rowspan="1" colspan="1">Reduzido</td><td align="center" rowspan="1" colspan="1">Reduzido</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Reduzida</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Reduzida</td></tr><tr><td rowspan="1" colspan="1">Dosagem lyso-gb3 (VR at&#x000e9; 0,8 ng/ml)</td><td align="center" rowspan="1" colspan="1">3,1</td><td align="center" rowspan="1" colspan="1">15,71</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">71,7</td><td align="center" rowspan="1" colspan="1">23,1</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Comprometimento Renal</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">Sim</td><td align="center" rowspan="1" colspan="1">N&#x000e3;o</td><td align="center" rowspan="1" colspan="1">Sim</td></tr></tbody></table><table-wrap-foot><attrib>* Ritmo card&#x000ed;aco n&#x000e3;o sinusal. Fonte: Autoria pr&#x000f3;pria.</attrib></table-wrap-foot></table-wrap>
</p><p>
<fig position="float" id="f01"><label>Figura 1</label><caption><title>&#x02013; Caso 1: (A) Eletrocardiograma com intervalo PR curto e invers&#x000e3;o de onda T de V3 a V6. (B) RMC demonstrando espessamento apical do VE. Caso 2: (C) Ecocardiograma com strain demonstrando acometimento do VE em regi&#x000f5;es anteriores, lateral e inferolateral basais. RMC com realce tardio na parede lateral do VE em eixo longo (D) e eixo curto (E). Caso 3: (F) Eletrocardiograma com fibrila&#x000e7;&#x000e3;o atrial e bloqueio de ramo direito.</title></caption><graphic xlink:href="0066-782X-abc-122-2-e20240535-gf01" position="float"/></fig>
</p><p>
<table-wrap position="float" id="t2"><label>Tabela 2</label><caption><title>&#x02013; Testes Gen&#x000e9;ticos</title></caption><table frame="hsides" rules="groups"><colgroup width="14%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Caso #1</th><th rowspan="1" colspan="1">Caso #2</th><th rowspan="1" colspan="1">Caso #3</th><th rowspan="1" colspan="1">Caso #4</th><th rowspan="1" colspan="1">Caso #5</th><th rowspan="1" colspan="1">Caso #6</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Teste Gen&#x000e9;tico</td><td align="center" rowspan="1" colspan="1">Painel</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Painel</td></tr><tr><td rowspan="1" colspan="1">Sequ&#x000ea;ncia refer&#x000ea;ncia</td><td align="center" rowspan="1" colspan="1">NM_000169.3</td><td align="center" rowspan="1" colspan="1">NM_000169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td></tr><tr><td rowspan="1" colspan="1">Coordenada Cromoss&#x000f4;mica (GRCh37)</td><td align="center" rowspan="1" colspan="1">chrX-100653021</td><td align="center" rowspan="1" colspan="1">chrX-100662818</td><td align="center" rowspan="1" colspan="1">chrX-100656700</td><td align="center" rowspan="1" colspan="1">chrX-100655733-100655734</td><td align="center" rowspan="1" colspan="1">chrX-100655733-100655734</td><td align="center" rowspan="1" colspan="1">chrX: 100653930</td></tr><tr><td rowspan="1" colspan="1">Variante c.DNA</td><td align="center" rowspan="1" colspan="1">c.1066C&#x0003e;T</td><td align="center" rowspan="1" colspan="1">c.73delG</td><td align="center" rowspan="1" colspan="1">c.467C&#x0003e;A</td><td align="center" rowspan="1" colspan="1">c.559_560del</td><td align="center" rowspan="1" colspan="1">c.559_560del</td><td align="center" rowspan="1" colspan="1">c.644A&#x0003e;G</td></tr><tr><td rowspan="1" colspan="1">Variante Prote&#x000ed;na</td><td align="center" rowspan="1" colspan="1">p.Arg356Trp</td><td align="center" rowspan="1" colspan="1">p.Asp25Thf*96</td><td align="center" rowspan="1" colspan="1">p.Ala156Asp</td><td align="center" rowspan="1" colspan="1">p.Met187ValfsTer6</td><td align="center" rowspan="1" colspan="1">p.Met187ValfsTer6</td><td align="center" rowspan="1" colspan="1">p.Asn215Ser</td></tr><tr><td rowspan="1" colspan="1">Zigosidade</td><td align="center" rowspan="1" colspan="1">Hemizigose</td><td align="center" rowspan="1" colspan="1">Heterozigose</td><td align="center" rowspan="1" colspan="1">Heterozigose</td><td align="center" rowspan="1" colspan="1">Hemizigose</td><td align="center" rowspan="1" colspan="1">Heterozigose</td><td align="center" rowspan="1" colspan="1">Hemizigose</td></tr><tr><td rowspan="1" colspan="1">Classifica&#x000e7;&#x000e3;o ACMG</td><td align="center" rowspan="1" colspan="1">Patog&#x000ea;nica</td><td align="center" rowspan="1" colspan="1">Provavelmente Patog&#x000ea;nica</td><td align="center" rowspan="1" colspan="1">Provavelmente Patog&#x000ea;nica</td><td align="center" rowspan="1" colspan="1">Patog&#x000ea;nica</td><td align="center" rowspan="1" colspan="1">Patog&#x000ea;nica</td><td align="center" rowspan="1" colspan="1">Patog&#x000ea;nica</td></tr></tbody></table><table-wrap-foot><attrib>Fonte: Autoria pr&#x000f3;pria.</attrib></table-wrap-foot></table-wrap>
</p></sec><sec><title>Caso 02 &#x02013; Fen&#x000f3;tipo de amiloidose card&#x000ed;aca</title><p>Paciente feminina, 57 anos, referia hipoacusia e zumbido de longa data assim como hipohidrose e dores em membros inferiores que se intensificavam com o frio durante a inf&#x000e2;ncia (
<xref rid="t1" ref-type="table">Tabela 1</xref>
). Diagn&#x000f3;stico pr&#x000e9;vio de fibrila&#x000e7;&#x000e3;o atrial (FA) permanente e palpita&#x000e7;&#x000f5;es recorrentes, havia passado por cinco procedimentos de abla&#x000e7;&#x000e3;o sem sucesso. Seu hist&#x000f3;rico familiar era frusto para doen&#x000e7;as de origem gen&#x000e9;tica. O ecocardiograma mostrou hipertrofia conc&#x000ea;ntrica moderada do VE, com &#x000ed;ndice de massa de 114 g/m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup> e fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o preservada. O strain longitudinal global (SLG) do VE era reduzido, principalmente nos segmentos basais das paredes anterior e lateral. A RMC revelou hipertrofia assim&#x000e9;trica do VE, predominando na regi&#x000e3;o inferolateral, com espessura de 15 mm, realce tardio heterog&#x000ea;neo de padr&#x000e3;o n&#x000e3;o isqu&#x000ea;mico e T1 nativo mioc&#x000e1;rdico reduzido (852 ms, refer&#x000ea;ncia ~1000 ms) (
<xref rid="f01" ref-type="fig">Figura 1</xref>
). O teste gen&#x000e9;tico identificou uma variante patog&#x000ea;nica no gene
<italic toggle="yes">GLA</italic>
(
<xref rid="t2" ref-type="table">Tabela 2</xref>
). A atividade da enzima alfa-galactosidase dosada foi reduzida, confirmando o diagn&#x000f3;stico de DF. A paciente tinha duas filhas e um filho, sendo que este &#x000fa;ltimo apresentou resultado positivo para a mesma variante no rastreio familiar.</p></sec><sec><title>Caso 03 &#x02013; Fibrila&#x000e7;&#x000e3;o atrial parox&#x000ed;stica e insufici&#x000ea;ncia renal</title><p>Paciente feminina, 52 anos, em hemodi&#x000e1;lise devido a doen&#x000e7;a renal cr&#x000f4;nica hipertensiva, foi encaminhada para avalia&#x000e7;&#x000e3;o cardiol&#x000f3;gica ap&#x000f3;s um epis&#x000f3;dio de FA, revertido com amiodarona, durante uma das sess&#x000f5;es de hemodi&#x000e1;lise. Sempre referiu dores neurop&#x000e1;ticas nas extremidades, que se intensificavam com frio e calor, assim como epis&#x000f3;dios frequentes de vertigem (
<xref rid="t1" ref-type="table">Tabela 1</xref>
). Seu ECG mostrava ritmo sinusal e intervalo PR curto assim como bloqueio do ramo direito (
<xref rid="f01" ref-type="fig">Figura 1</xref>
). Foi solicitado um ecocardiograma que evidenciou espessura do septo interventricular de 21 mm e da parede lateral de 14 mm, com fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o preservada e sem obstru&#x000e7;&#x000e3;o na via de sa&#x000ed;da do VE.</p><p>A paciente apresentou um hist&#x000f3;rico familiar relevante, incluindo o falecimento da m&#x000e3;e por doen&#x000e7;a renal cr&#x000f4;nica, dois irm&#x000e3;os em hemodi&#x000e1;lise e uma irm&#x000e3; com doen&#x000e7;a renal cr&#x000f4;nica n&#x000e3;o dial&#x000ed;tica. Diante do hist&#x000f3;rico familiar associado a problemas renais e card&#x000ed;acos, foi realizada uma an&#x000e1;lise gen&#x000e9;tica que revelou uma variante patog&#x000ea;nica no gene
<italic toggle="yes">GLA</italic>
(
<xref rid="t2" ref-type="table">Tabela 2</xref>
), tamb&#x000e9;m constatada em seus irm&#x000e3;os, confirmando o diagn&#x000f3;stico de DF na fam&#x000ed;lia.</p></sec><sec><title>Caso 04 &#x02013; Assintom&#x000e1;tico com hipertrofia de parede lateral</title><p>Paciente masculino, 40 anos, relatou intoler&#x000e2;ncia ao calor e aus&#x000ea;ncia de suor desde a inf&#x000e2;ncia (
<xref rid="t1" ref-type="table">Tabela 1</xref>
). Referia que a m&#x000e3;e possu&#x000ed;a o diagn&#x000f3;stico de arritmia card&#x000ed;aca. Seu ECG mostrou ritmo sinusal com intervalo PR curto e sinais de SVE. No ecocardiograma, o &#x000ed;ndice de massa do VE foi de 142 g/m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>, com espessura septal de 10 mm, parede lateral de 12 mm e hipertrofia dos m&#x000fa;sculos papilares (
<xref rid="f02" ref-type="fig">Figura 2</xref>
). Exames bioqu&#x000ed;micos revelaram comprometimento da fun&#x000e7;&#x000e3;o renal e protein&#x000fa;ria de 1,55 g/24h. Diante desses achados, suspeitou-se de DF. A dosagem da atividade da enzima alfa-galactosidase mostrou-se reduzida (
<xref rid="t1" ref-type="table">Tabela 1</xref>
) e o teste gen&#x000e9;tico (Sanger) revelou uma variante patog&#x000ea;nica no gene
<italic toggle="yes">GLA</italic>
(
<xref rid="t2" ref-type="table">Tabela 2</xref>
), identificada de igual maneira em sua genitora.</p><p>
<fig position="float" id="f02"><label>Figura 2</label><caption><title>&#x02013; Caso 4: (G) Imagens ecocardiogr&#x000e1;ficas demonstrando espessamento do m&#x000fa;sculo papilar, aumento da espessura global do VE e t&#x000e9;cnica de Strain com acometimento do segmento basal das paredes inferior, lateral e infero-lateral. Caso 5: (H) Imagem ecocardiogr&#x000e1;fica, exibe espessamento da parede septal e lateral do VE. Caso 6: (I) Ecocardiograma revela espessamento do VE assim como di&#x000e2;metro diast&#x000f3;lico final aumentado. Imagens de microoscopia &#x000f3;ptica, com colora&#x000e7;&#x000e3;o com tricr&#x000f4;mico de Masson mostrando &#x000e1;reas de fibrose (J) e em colora&#x000e7;&#x000e3;o hematoxilina eosina demonstrando extensa vacuoliza&#x000e7;&#x000e3;o do citoplasma dos cardiomi&#x000f3;citos (K). (L) Vista coronal de cora&#x000e7;&#x000e3;o explantado com aumento de espessura de todo mioc&#x000e1;rdio.</title></caption><graphic xlink:href="0066-782X-abc-122-2-e20240535-gf02" position="float"/></fig>
</p></sec><sec><title>Caso 05 &#x02013; Insufici&#x000ea;ncia card&#x000ed;aca com fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o preservada</title><p>Paciente feminina, 68 anos, relatava dispneia aos esfor&#x000e7;os, que comprometiam significativamente suas atividades cotidianas. Referia epis&#x000f3;dios de dor precordial at&#x000ed;pica, sem rela&#x000e7;&#x000e3;o com esfor&#x000e7;o, (
<xref rid="t1" ref-type="table">Tabela 1</xref>
) negando demais queixas. Questionada sobre seu hist&#x000f3;rico familiar, relatou que seu pai faleceu aos 45 anos devido a uma causa indeterminada. O ECG evidenciou intervalo PR curto, dist&#x000fa;rbio de condu&#x000e7;&#x000e3;o intraventricular e altera&#x000e7;&#x000f5;es difusas da repolariza&#x000e7;&#x000e3;o ventricular. O ecocardiograma mostrou hipertrofia ventricular conc&#x000ea;ntrica do VE, assim como aumento das espessuras do septo interventricular e da parede lateral respectivamente de 19 mm e 18 mm. A massa indexada do VE calculada foi de 320 g/m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>. Realizado SLG com redu&#x000e7;&#x000e3;o de seus valores na regi&#x000e3;o &#x000ed;nfero-latero-basal (
<xref rid="f02" ref-type="fig">Figura 2</xref>
). Um painel gen&#x000e9;tico para avalia&#x000e7;&#x000e3;o de genoc&#x000f3;pias de CMH demostrou presen&#x000e7;a de variante patog&#x000ea;nica no gene
<italic toggle="yes">GLA</italic>
, confirmando a DF (
<xref rid="t2" ref-type="table">Tabela 2</xref>
). Dois filhos da paciente foram submetidos a rastreamento familiar e a variante foi identificada em um deles.</p></sec><sec><title>Caso 06 &#x02013; Insufici&#x000ea;ncia card&#x000ed;aca com fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o reduzida</title><p>Paciente masculino, 64 anos, com hist&#x000f3;rico de CMH diagnosticada h&#x000e1; 30 anos, sem outros sintomas sist&#x000ea;micos (
<xref rid="t1" ref-type="table">Tabela 1</xref>
), foi internado por descompensa&#x000e7;&#x000e3;o de insufici&#x000ea;ncia card&#x000ed;aca perfil C. O hist&#x000f3;rico familiar inclu&#x000ed;a um irm&#x000e3;o tamb&#x000e9;m com o diagn&#x000f3;stico de CMH. Apesar do tratamento otimizado e da terapia de ressincroniza&#x000e7;&#x000e3;o card&#x000ed;aca realizada tr&#x000ea;s anos antes, o ecocardiograma revelou fra&#x000e7;&#x000e3;o de eje&#x000e7;&#x000e3;o do VE de 29% e hipertrofia ventricular com espessuras de septo e parede lateral de 17 mm (
<xref rid="f02" ref-type="fig">Figura 2</xref>
). Devido &#x000e0; refratariedade &#x000e0; retirada do inotr&#x000f3;pico, o paciente foi considerado em fase terminal da doen&#x000e7;a e submetido com sucesso a transplante card&#x000ed;aco.</p><p>A an&#x000e1;lise histopatol&#x000f3;gica da pe&#x000e7;a explantada (
<xref rid="f02" ref-type="fig">Figura 2</xref>
) e um painel gen&#x000e9;tico (
<xref rid="t2" ref-type="table">Tabela 2</xref>
) revelaram uma variante patog&#x000ea;nica no gene
<italic toggle="yes">GLA</italic>
, com n&#x000ed;veis reduzidos da atividade da enzima alfa-galactosidase. Seu irm&#x000e3;o tamb&#x000e9;m foi sequenciado para o mesmo gene, sendo encontrada a mesma variante, de origem materna.</p></sec></sec><sec sec-type="discussion"><title>Discuss&#x000e3;o</title><p>A DF &#x000e9; uma condi&#x000e7;&#x000e3;o gen&#x000e9;tica ligada ao cromossomo X que se manifesta de maneira diferente em homens e mulheres. Existem dois fen&#x000f3;tipos principais: o cl&#x000e1;ssico, mais comum em homens, caracterizado pela perda total da fun&#x000e7;&#x000e3;o da enzima &#x003b1;-GalA, resultando em sintomas multissist&#x000ea;micos; e o n&#x000e3;o cl&#x000e1;ssico, com variantes de
<italic toggle="yes">late-onset</italic>
que levam a uma progress&#x000e3;o mais lenta da doen&#x000e7;a, geralmente afetando apenas o cora&#x000e7;&#x000e3;o ou os rins.<sup>
<xref rid="B2" ref-type="bibr">2</xref>
,
<xref rid="B3" ref-type="bibr">3</xref>
</sup> Novos estudos mostraram a tend&#x000ea;ncia de variantes com perda de fun&#x000e7;&#x000e3;o gerarem um fen&#x000f3;tipo com atividade enzim&#x000e1;tica bastante diminu&#x000ed;da e quadro cl&#x000ed;nico cl&#x000e1;ssico, enquanto variantes
<italic toggle="yes">missense</italic>
est&#x000e3;o associadas a fen&#x000f3;tipos de in&#x000ed;cio tardio (
<italic toggle="yes">late-onset</italic>
).<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup> Na s&#x000e9;rie descrita, tr&#x000ea;s pacientes tinham variantes que resultaram em
<italic toggle="yes">stop codon</italic>
precoce, por&#x000e9;m apenas o caso 4 evoluiu conforme descrito na literatura.</p><p>N&#x000e3;o s&#x000f3; a variante gen&#x000e9;tica, mas o lyso-Gb3, forma desacetilada do Gb3, &#x000e9; um marcador da DF fortemente relacionado com seu fen&#x000f3;tipo. Seu valor tende a ser elevado em pacientes com a forma cl&#x000e1;ssica e mais baixo na forma n&#x000e3;o cl&#x000e1;ssica.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup></p><p>Pacientes do sexo masculino com DF de in&#x000ed;cio tardio apresentam maior atividade residual de &#x003b1;-Gal A em compara&#x000e7;&#x000e3;o com a DF cl&#x000e1;ssica, embora ainda muito abaixo dos valores normais.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup> Em mulheres heterozigotas, a atividade de &#x003b1;-Gal A pode ser normal ou ligeiramente deficiente, muitas vezes com evolu&#x000e7;&#x000e3;o cl&#x000ed;nica assintom&#x000e1;tica, o que desencoraja a dosagem s&#x000e9;rica desse marcador nessa popula&#x000e7;&#x000e3;o, sendo o diagn&#x000f3;stico realizado por meio da confirma&#x000e7;&#x000e3;o do gen&#x000f3;tipo. Existe a possibilidade, em mulheres heterozigotas, da inativa&#x000e7;&#x000e3;o do cromossomo X saud&#x000e1;vel, sendo o que cont&#x000e9;m a variante o que prepondera, gerando sintomas graves com a apresenta&#x000e7;&#x000e3;o cl&#x000ed;nica cl&#x000e1;ssica da doen&#x000e7;a. Essa express&#x000e3;o gen&#x000e9;tica se d&#x000e1; de forma rand&#x000f4;mica em cada c&#x000e9;lula do organismo.<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup></p><p>Manifesta&#x000e7;&#x000f5;es t&#x000ed;picas da DF, como angioqueratomas e c&#x000f3;rnea verticilata, s&#x000e3;o menos frequentes, sendo mais comuns em fen&#x000f3;tipos cl&#x000e1;ssicos. Pacientes adultos com altera&#x000e7;&#x000f5;es estruturais no mioc&#x000e1;rdio, aumento progressivo ao longo do tempo do espessamento mioc&#x000e1;rdico, dist&#x000fa;rbios de condu&#x000e7;&#x000e3;o, doen&#x000e7;a renal cr&#x000f4;nica e sintomas neurol&#x000f3;gicos, especialmente acroparestesias e/ou hipohidrose devem ser investigados ativamente para DF, assim como seus familiares.</p><p>A manifesta&#x000e7;&#x000e3;o card&#x000ed;aca t&#x000ed;pica da DF &#x000e9; a hipertrofia ventricular esquerda conc&#x000ea;ntrica, comum a partir da terceira d&#x000e9;cada de vida. Essa hipertrofia pode ser confundida com outras condi&#x000e7;&#x000f5;es, como CMH e amiloidose card&#x000ed;aca.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup> Estudos indicam que a DF est&#x000e1; presente em 0,5 a 3% dos casos diagnosticados como CMH.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup> Na s&#x000e9;rie de casos apresentada, dois pacientes tiveram o diagn&#x000f3;stico de DF erroneamente atribu&#x000ed;do &#x000e0; CMH, resultando em atraso na TRE e, em um caso, a necessidade de transplante card&#x000ed;aco.</p><p>No ECG, altera&#x000e7;&#x000f5;es como a redu&#x000e7;&#x000e3;o do intervalo PR e a preval&#x000ea;ncia aumentada de FA s&#x000e3;o indicativas de DF. A ecocardiografia &#x000e9; essencial para o diagn&#x000f3;stico e monitoramento da cardiomiopatia de Fabry, revelando, entre outros achados, o espessamento da parede ventricular e a disfun&#x000e7;&#x000e3;o diast&#x000f3;lica.<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup></p><p>A RMC tamb&#x000e9;m &#x000e9; &#x000fa;til, destacando a fibrose nos segmentos basais inferolaterais e a redu&#x000e7;&#x000e3;o dos valores no mapa T1, que podem ser indicadores precoces da DF.</p><p>O tratamento espec&#x000ed;fico consiste na TRE, que visa substituir a enzima que est&#x000e1; em falta, evitando, consequentemente, o ac&#x000fa;mulo de Gb3. No Brasil, temos a alfa-galsidase e a beta-galsidase, ambas administradas por via intravenosa a cada duas semanas. Mais recentemente, uma nova proposta de terapia, as chaperonas, surgiu para aumentar o arsenal terap&#x000ea;utico no tratamento da DF. Todavia, essa classe demonstrou efic&#x000e1;cia apenas em subtipos espec&#x000ed;ficos de variantes patog&#x000ea;nicas, sendo necess&#x000e1;ria uma valida&#x000e7;&#x000e3;o
<italic toggle="yes">in vitro</italic>
da medica&#x000e7;&#x000e3;o para a variante espec&#x000ed;fica do paciente antes de sua aplica&#x000e7;&#x000e3;o. As chaperonas atuam mantendo a estabilidade da prote&#x000ed;na disfuncional, auxiliando em seu correto dobramento e, consequentemente, preservando sua atividade.<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup></p><p>Por fim, uma investiga&#x000e7;&#x000e3;o cl&#x000ed;nica detalhada, junto ao aux&#x000ed;lio de uma avalia&#x000e7;&#x000e3;o gen&#x000e9;tica conduzida por um profissional experiente, &#x000e9; crucial para o diagn&#x000f3;stico da DF. A capacita&#x000e7;&#x000e3;o constante dos cardiologistas &#x000e9; fundamental para aumentar o reconhecimento da doen&#x000e7;a e viabilizar interven&#x000e7;&#x000f5;es precoces, que podem retardar sua progress&#x000e3;o e prevenir complica&#x000e7;&#x000f5;es graves, garantindo um melhor progn&#x000f3;stico para os pacientes.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Vincula&#x000e7;&#x000e3;o acad&#x000ea;mica:</bold> N&#x000e3;o h&#x000e1; vincula&#x000e7;&#x000e3;o deste estudo a programas de p&#x000f3;s-gradua&#x000e7;&#x000e3;o.</p></fn><fn fn-type="other"><p><bold>Aprova&#x000e7;&#x000e3;o &#x000e9;tica e consentimento informado:</bold> Este estudo foi aprovado pelo Comit&#x000ea; de &#x000c9;tica da Associa&#x000e7;&#x000e3;o Lar S&#x000e3;o Francisco de Assis da Provid&#x000ea;ncia de Deus sob o n&#x000fa;mero de protocolo 63892722.1.0000.5514. Todos os procedimentos envolvidos nesse estudo est&#x000e3;o de acordo com a Declara&#x000e7;&#x000e3;o de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes inclu&#x000ed;dos no estudo.</p></fn><fn fn-type="financial-disclosure"><p><bold>Fontes de financiamento:</bold> O presente estudo n&#x000e3;o teve fontes de financiamento externas.</p></fn></fn-group><ref-list><title>Refer&#x000ea;ncias</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pieroni</surname><given-names>M</given-names></name>
<name><surname>Moon</surname><given-names>JC</given-names></name>
<name><surname>Arbustini</surname><given-names>E</given-names></name>
<name><surname>Barriales-Villa</surname><given-names>R</given-names></name>
<name><surname>Camporeale</surname><given-names>A</given-names></name>
<name><surname>Vujkovac</surname><given-names>AC</given-names></name>
<etal>et al</etal>
</person-group><article-title>Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week</article-title><source>
J Am Coll Cardiol
</source><year>2021</year><volume>77</volume><issue>7</issue><fpage>922</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.12.024</pub-id><pub-id pub-id-type="pmid">33602475</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silva</surname><given-names>CAB</given-names></name>
<name><surname>Andrade</surname><given-names>LGM</given-names></name>
<name><surname>Vaisbich</surname><given-names>MH</given-names></name>
<name><surname>Barreto</surname><given-names>FC</given-names></name>
</person-group><article-title>Brazilian Consensus Recommendations for the Diagnosis, Screening, and Treatment of Individuals with Fabry Disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021</article-title><source>
J Bras Nefrol
</source><year>2022</year><volume>44</volume><issue>2</issue><fpage>249</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1590/2175-8239-JBN-2021-0208</pub-id><pub-id pub-id-type="pmid">35212703</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Germain</surname><given-names>DP</given-names></name>
<name><surname>Brand</surname><given-names>E</given-names></name>
<name><surname>Burlina</surname><given-names>A</given-names></name>
<name><surname>Cecchi</surname><given-names>F</given-names></name>
<name><surname>Garman</surname><given-names>SC</given-names></name>
<name><surname>Kempf</surname><given-names>J</given-names></name>
<etal>et al</etal>
</person-group><article-title>Phenotypic Characteristics of the p.Asn215Ser (p.N215S) GLA Mutation in Male and Female Patients with Fabry Disease: A Multicenter Fabry Registry Study</article-title><source>
Mol Genet Genomic Med
</source><year>2018</year><volume>6</volume><issue>4</issue><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/mgg3.389</pub-id><pub-id pub-id-type="pmid">29649853</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortiz</surname><given-names>A</given-names></name>
<name><surname>Germain</surname><given-names>DP</given-names></name>
<name><surname>Desnick</surname><given-names>RJ</given-names></name>
<name><surname>Politei</surname><given-names>J</given-names></name>
<name><surname>Mauer</surname><given-names>M</given-names></name>
<name><surname>Burlina</surname><given-names>A</given-names></name>
<etal>et al</etal>
</person-group><article-title>Fabry Disease Revisited: Management and Treatment Recommendations for Adult Patients</article-title><source>
Mol Genet Metab
</source><year>2018</year><volume>123</volume><issue>4</issue><fpage>416</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2018.02.014</pub-id><pub-id pub-id-type="pmid">29530533</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arends</surname><given-names>M</given-names></name>
<name><surname>Wanner</surname><given-names>C</given-names></name>
<name><surname>Hughes</surname><given-names>D</given-names></name>
<name><surname>Mehta</surname><given-names>A</given-names></name>
<name><surname>Oder</surname><given-names>D</given-names></name>
<name><surname>Watkinson</surname><given-names>OT</given-names></name>
<etal>et al</etal>
</person-group><article-title>Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study</article-title><source>
J Am Soc Nephrol
</source><year>2017</year><volume>28</volume><issue>5</issue><fpage>1631</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1681/ASN.2016090964</pub-id><pub-id pub-id-type="pmid">27979989</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Echevarria</surname><given-names>L</given-names></name>
<name><surname>Benistan</surname><given-names>K</given-names></name>
<name><surname>Toussaint</surname><given-names>A</given-names></name>
<name><surname>Dubourg</surname><given-names>O</given-names></name>
<name><surname>Hagege</surname><given-names>AA</given-names></name>
<name><surname>Eladari</surname><given-names>D</given-names></name>
<etal>et al</etal>
</person-group><article-title>X-Chromosome Inactivation in Female Patients with Fabry Disease</article-title><source>
Clin Genet
</source><year>2016</year><volume>89</volume><issue>1</issue><fpage>44</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1111/cge.12613</pub-id><pub-id pub-id-type="pmid">25974833</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>F</given-names></name>
<name><surname>Antunes</surname><given-names>MO</given-names></name>
<name><surname>Hotta</surname><given-names>VT</given-names></name>
<name><surname>Rochitte</surname><given-names>CE</given-names></name>
<name><surname>Mady</surname><given-names>C</given-names></name>
</person-group><article-title>Deposit Diseases as Differential Diagnosis of Left Ventricular Hypertrophy in Patients with Heart Failure and Preserved Systolic Function</article-title><source>
Arq Bras Cardiol
</source><year>2019</year><volume>113</volume><issue>5</issue><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.36660/abc.20180370</pub-id><pub-id pub-id-type="pmid">31800724</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nordin</surname><given-names>S</given-names></name>
<name><surname>Kozor</surname><given-names>R</given-names></name>
<name><surname>Medina-Menacho</surname><given-names>K</given-names></name>
<name><surname>Abdel-Gadir</surname><given-names>A</given-names></name>
<name><surname>Baig</surname><given-names>S</given-names></name>
<name><surname>Sado</surname><given-names>DM</given-names></name>
<etal>et al</etal>
</person-group><article-title>Proposed Stages of Myocardial Phenotype Development in Fabry Disease</article-title><source>
JACC Cardiovasc Imaging
</source><year>2019</year><volume>12</volume><issue>8 Pt 2</issue><fpage>1673</fpage><lpage>1683</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2018.03.020</pub-id><pub-id pub-id-type="pmid">29778854</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van der Veen</surname><given-names>SJ</given-names></name>
<name><surname>Hollak</surname><given-names>CEM</given-names></name>
<name><surname>van Kuilenburg</surname><given-names>ABP</given-names></name>
<name><surname>Langeveld</surname><given-names>M</given-names></name>
</person-group><article-title>Developments in the Treatment of Fabry Disease</article-title><source>
J Inherit Metab Dis
</source><year>2020</year><volume>43</volume><issue>5</issue><fpage>908</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1002/jimd.12228</pub-id><pub-id pub-id-type="pmid">32083331</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="TRen" xml:lang="en"><front-stub><article-id pub-id-type="doi">10.36660/abc.20240535i</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Fabry Disease and Its Different Phenotypes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8071-924X</contrib-id><name><surname>Antunes</surname><given-names>Murillo Oliveira</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2001" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-0241-5535</contrib-id><name><surname>Nastari</surname><given-names>Rafael Ruas</given-names></name><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arteaga-Fernandez</surname><given-names>Edmundo</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-1246-4838</contrib-id><name><surname>Lizandro</surname><given-names>Marcelle G. Henriques</given-names></name><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>El-Feghaly</surname><given-names>William Batah</given-names></name><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Guilherme Jos&#x000e9; dos Santos</given-names></name><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Alan Silva</given-names></name><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Leguizamon</surname><given-names>Juliana Alzira Gonzales Oliveira</given-names></name><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Correia</surname><given-names>Vinicius Machado</given-names></name><role>Conception and design of the research</role><role>Writing of the manuscript</role><role>Critical revision of the manuscript for content</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Madrini</surname><given-names>Vagner</given-names><suffix>Junior</suffix></name><role>Conception and design of the research</role><role>Acquisition of data</role><role>Data analysis and interpretation</role><role>Writing of the manuscript</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9323-8805</contrib-id><name><surname>Fernandes</surname><given-names>F&#x000e1;bio</given-names></name><role>Conception and design of the research</role><role>Acquisition of data</role><xref rid="aff1001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1001">
<label>1</label>
<country country="BR">Brazil</country>
<institution content-type="original">Instituto do Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP &#x02013; Brazil</institution>
</aff><aff id="aff2001">
<label>2</label>
<country country="BR">Brazil</country>
<institution content-type="original">Universidade S&#x000e3;o Francisco, Bragan&#x000e7;a Paulista, SP &#x02013; Brazil</institution>
</aff><author-notes><corresp id="c01001">
<label>Mailing Address</label>
: Rafael Ruas Nastari &#x02022; Rua Doutor Diogo de Faria, 1077, apto. 62. Postal Code 04037-003, S&#x000e3;o Paulo, SP &#x02013; Brazil E-mail: rafael_nastari@msn.com</corresp><fn fn-type="COI-statement"><p><bold>Potential conflict of interest:</bold> No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="edited-by"><p><bold>Editor responsible for the review:</bold> Nat&#x000e1;lia Olivetti</p></fn></author-notes><abstract><title>Abstract</title><p>Fabry disease (FD) is an X-linked genetic condition caused by variants in the
<italic toggle="yes">GLA</italic>
gene causing enzyme &#x003b1;-galactosidase A deficiency and accumulation of globotriaosylceramide (Gb3) in tissues such as the heart, kidneys, and the nervous system. This study reports a case series of patients with FD, highlighting the phenotypic diversity of the disease, which can be confused with other cardiological conditions. When properly indicated, genetic evaluation, combined with biomarker dosage and &#x003b1;-galactosidase enzymatic activity, is key for an accurate diagnosis. Early diagnosis of FD is fundamental for initiating treatments that can slow disease progression and prevent serious complications, reinforcing the need for greater awareness about this condition among cardiologists.</p></abstract><kwd-group><kwd>Fabry Disease</kwd><kwd>Cardiomyopathies</kwd><kwd>Genetics</kwd></kwd-group></front-stub><body><sec sec-type="intro"><title>Introduction</title><p>FD is an X-linked lysosomal storage disorder caused by pathogenic variants in the
<italic toggle="yes">GLA</italic>
gene, which result in significantly reduced &#x003b1;-galactosidase A (&#x003b1;-GalA) enzyme activity. This leads to globotriaosylceramide (Gb3) accumulation in tissues such as the heart, kidneys, blood vessels, and the peripheral nervous system. Although incidence estimates vary, recent studies, including newborn screening and biobank analyses, suggest that the true prevalence may be underestimated, with an incidence of up to 1 in 5,732 for late-onset variants.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>With the introduction of enzyme replacement therapy (ERT), early diagnosis has become crucial to slowing disease progression. This case series demonstrates the different phenotypes of FD, which can mimic other heart diseases, to facilitate the early recognition of the condition.</p><sec><title>Case 01 &#x02013; Apical hypertrophic cardiomyopathy</title><p>A 29-year-old male patient, with no comorbidities or family history of heart disease, complained of tingling and burning in his legs as well as a spot in the abdominal region (angiokeratomas). He sought medical care due to atypical precordial pain (
<xref rid="t1001" ref-type="table">Table 1</xref>
). The electrocardiogram (ECG) showed a short PR interval and signs of left ventricular overload (LVO) with T wave inversion in V3-V6 (
<xref rid="f01001" ref-type="fig">Figure 1</xref>
). The echocardiogram revealed asymmetric hypertrophy of the left ventricle (LV) in the apical region, with a maximum thickness of 17 mm and no obstruction in the LV outflow tract. The patient was initially diagnosed with non-obstructive hypertrophic cardiomyopathy (HCM), apical form. Cardiac magnetic resonance imaging (CMRI) showed circumferential hypertrophy in the middle and apical segments, with a thickness of 21 mm and multifocal myocardial late enhancement of a non-ischemic pattern (
<xref rid="f01001" ref-type="fig">Figure 1</xref>
). Genetic investigation revealed a pathogenic variant in the
<italic toggle="yes">GLA</italic>
gene (
<xref rid="t2001" ref-type="table">Table 2</xref>
), and the alpha-galactosidase enzyme dosage showed a reduced value, confirming the diagnosis of FD. Family screening was performed and the same variant was found in the patient&#x02019;s mother.</p><p>
<table-wrap position="float" id="t1001"><label>Table 1</label><caption><title>&#x02013; Clinical and Laboratory Characteristics</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Case #1</th><th rowspan="1" colspan="1">Case #2</th><th rowspan="1" colspan="1">Case #3</th><th rowspan="1" colspan="1">Case #4</th><th rowspan="1" colspan="1">Case #5</th><th rowspan="1" colspan="1">Case #6</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, years</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td></tr><tr><td rowspan="1" colspan="1">Phenotype</td><td align="center" rowspan="1" colspan="1">Apical HCM</td><td align="center" rowspan="1" colspan="1">Cardiac amyloidosis</td><td align="center" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">Asymptomatic</td><td align="center" rowspan="1" colspan="1">(Heart Failure with Preserved Ejection Fraction) HFpEF</td><td align="center" rowspan="1" colspan="1">(Heart Failure with Reduced Ejection Fraction) HFrEF</td></tr><tr><td rowspan="1" colspan="1">Clinical Presentation</td><td align="center" rowspan="1" colspan="1">Cardiovascular symptoms &#x02013; Chest pain</td><td align="center" rowspan="1" colspan="1">Hypohidrosis, acroparesthesia, and palpitations</td><td align="center" rowspan="1" colspan="1">Palpitations, acroparesthesia, and vertigo</td><td align="center" rowspan="1" colspan="1">Anhidrosis and heat intolerance</td><td align="center" rowspan="1" colspan="1">Cardiovascular symptoms &#x02013; Dyspnea</td><td align="center" rowspan="1" colspan="1">Cardiovascular symptoms &#x02013; Dyspnea</td></tr><tr><td rowspan="1" colspan="1">Short PR interval</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">*</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">*</td></tr><tr><td rowspan="1" colspan="1">LVEF, %</td><td align="center" rowspan="1" colspan="1">Preserved</td><td align="center" rowspan="1" colspan="1">Preserved</td><td align="center" rowspan="1" colspan="1">Preserved</td><td align="center" rowspan="1" colspan="1">Preserved</td><td align="center" rowspan="1" colspan="1">Preserved</td><td align="center" rowspan="1" colspan="1">Reduced</td></tr><tr><td rowspan="1" colspan="1">Maximum thickness, mm</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td rowspan="1" colspan="1">&#x003b1;-galactosidase dosage</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Reduced</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Reduced</td></tr><tr><td rowspan="1" colspan="1">Lyso-gb3 dosage (range: up to 0.8 ng/ml)</td><td align="center" rowspan="1" colspan="1">3.1</td><td align="center" rowspan="1" colspan="1">15.71</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">71.7</td><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Renal impairment</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table-wrap-foot><attrib>* Non-sinus heart rhythm. Source: The authors.</attrib></table-wrap-foot></table-wrap>
</p><p>
<fig position="float" id="f01001"><label>Figure 1</label><caption><title>&#x02013; Case 1: (A) Electrocardiogram with short PR interval and T wave inversion from V3 to V6. (B) CCMRI demonstrating LV apical thickening. Case 2: (C) Strain echocardiogram demonstrating LV involvement in anterior, lateral, and basal inferolateral regions. CCMRI with delayed enhancement in the LV lateral wall in the long axis (D) and short axis (E). Case 3: (F) Electrocardiogram with atrial fibrillation and right bundle branch block.</title></caption><graphic xlink:href="0066-782X-abc-122-2-e20240535-gf01-en" position="float"/></fig>
</p><p>
<table-wrap position="float" id="t2001"><label>Table 2</label><caption><title>&#x02013; Genetic Tests</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1">Case #1</th><th rowspan="1" colspan="1">Case #2</th><th rowspan="1" colspan="1">Case #3</th><th rowspan="1" colspan="1">Case #4</th><th rowspan="1" colspan="1">Case #5</th><th rowspan="1" colspan="1">Case #6</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Genetic Testing</td><td align="center" rowspan="1" colspan="1">Panel</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Sanger</td><td align="center" rowspan="1" colspan="1">Panel</td></tr><tr><td rowspan="1" colspan="1">Reference sequence</td><td align="center" rowspan="1" colspan="1">NM_000169.3</td><td align="center" rowspan="1" colspan="1">NM_000169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td><td align="center" rowspan="1" colspan="1">NM_00169.3</td></tr><tr><td rowspan="1" colspan="1">Chromosome Coordinate (GRCh37)</td><td align="center" rowspan="1" colspan="1">chrX-100653021</td><td align="center" rowspan="1" colspan="1">chrX-100662818</td><td align="center" rowspan="1" colspan="1">chrX-100656700</td><td align="center" rowspan="1" colspan="1">chrX-100655733-100655734</td><td align="center" rowspan="1" colspan="1">chrX-100655733-100655734</td><td align="center" rowspan="1" colspan="1">chrX: 100653930</td></tr><tr><td rowspan="1" colspan="1">c.DNA variant</td><td align="center" rowspan="1" colspan="1">c.1066C&#x0003e;T</td><td align="center" rowspan="1" colspan="1">c.73delG</td><td align="center" rowspan="1" colspan="1">c.467C&#x0003e;A</td><td align="center" rowspan="1" colspan="1">c.559_560del</td><td align="center" rowspan="1" colspan="1">c.559_560del</td><td align="center" rowspan="1" colspan="1">c.644A&#x0003e;G</td></tr><tr><td rowspan="1" colspan="1">Protein Variant</td><td align="center" rowspan="1" colspan="1">p.Arg356Trp</td><td align="center" rowspan="1" colspan="1">p.Asp25Thf*96</td><td align="center" rowspan="1" colspan="1">p.Ala156Asp</td><td align="center" rowspan="1" colspan="1">p.Met187ValfsTer6</td><td align="center" rowspan="1" colspan="1">p.Met187ValfsTer6</td><td align="center" rowspan="1" colspan="1">p.Asn215Ser</td></tr><tr><td rowspan="1" colspan="1">Zygosity</td><td align="center" rowspan="1" colspan="1">Hemizygosity</td><td align="center" rowspan="1" colspan="1">Heterozygosity</td><td align="center" rowspan="1" colspan="1">Heterozygosity</td><td align="center" rowspan="1" colspan="1">Hemizygosity</td><td align="center" rowspan="1" colspan="1">Heterozygosity</td><td align="center" rowspan="1" colspan="1">Hemizygosity</td></tr><tr><td rowspan="1" colspan="1">ACMG Classification</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">Probably Pathogenic</td><td align="center" rowspan="1" colspan="1">Probably Pathogenic</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">Pathogenic</td></tr></tbody></table><table-wrap-foot><attrib>Source: The authors.</attrib></table-wrap-foot></table-wrap>
</p></sec><sec><title>Case 02 &#x02013; Cardiac Amyloidosis Phenotype</title><p>A 57-year-old female patient, reported long-standing hearing loss and tinnitus, as well as hypohidrosis and pain in the lower limbs exacerbated by cold weather during childhood (
<xref rid="t1001" ref-type="table">Table 1</xref>
). Previously diagnosed with permanent atrial fibrillation (AF) and recurrent palpitations, she had undergone five unsuccessful ablation procedures. Her family history was poor for diseases of genetic origin. The echocardiogram showed moderate concentric LV hypertrophy, with a 114 g/m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>mass index and preserved ejection fraction. The global longitudinal strain (GLS) of the LV was reduced, mainly in the basal segments of the anterior and lateral walls. CMRI revealed asymmetric LV hypertrophy, predominating in the inferolateral region, with a thickness of 15 mm, heterogeneous late enhancement of a non-ischemic pattern, and reduced myocardial native T1 (852 ms, reference ~1000 ms) (
<xref rid="f01001" ref-type="fig">Figure 1</xref>
). Genetic testing identified a pathogenic variant in the
<italic toggle="yes">GLA</italic>
gene (
<xref rid="t2001" ref-type="table">Table 2</xref>
). The measured alpha-galactosidase enzyme activity was reduced, confirming the diagnosis of FD. The patient had two daughters and one son. The son tested positive for the same variant in family screening.</p></sec><sec><title>Case 03 &#x02013; Paroxysmal atrial fibrillation and renal failure</title><p>A 52-year-old female patient, on hemodialysis due to hypertensive chronic kidney disease was referred for cardiological evaluation after an episode of AF, reversed with amiodarone, during one of the hemodialysis sessions. She had always reported neuropathic pain in the extremities that worsened with cold and hot weather, as well as frequent episodes of vertigo (
<xref rid="t1001" ref-type="table">Table 1</xref>
). Her ECG showed sinus rhythm and short PR interval as well as right bundle branch block (
<xref rid="f01001" ref-type="fig">Figure 1</xref>
). An echocardiogram was requested, which showed the interventricular septum was 21 mm thick and the lateral wall was 14 mm thick, with preserved ejection fraction and no obstruction in the LV outflow tract.</p><p>The patient reported a significant family history, including the death of her mother from chronic kidney disease, two brothers on hemodialysis, and a sister with non-dialysis chronic kidney disease. Given the family history associated with kidney and heart problems, a genetic analysis was performed which revealed a pathogenic variant in the
<italic toggle="yes">GLA</italic>
gene (
<xref rid="t2001" ref-type="table">Table 2</xref>
), also found in her brother, confirming the diagnosis of FD in the family.</p></sec><sec><title>Case 04 &#x02013; Asymptomatic with lateral wall hypertrophy</title><p>A 40-year-old male patient, reported heat intolerance and absence of sweating since childhood (
<xref rid="t1001" ref-type="table">Table 1</xref>
). He said that his mother had been diagnosed with cardiac arrhythmia. His ECG showed sinus rhythm with a short PR interval and signs of LVO. On echocardiogram, the left ventricular mass index was 142 g/m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>, with septal thickness of 10 mm, lateral wall thickness of 12 mm, and hypertrophy of the papillary muscles (
<xref rid="f02001" ref-type="fig">Figure 2</xref>
). Biochemical tests revealed impaired renal function and proteinuria of 1.55 g/24h. Given these findings, FD was suspected. The alpha-galactosidase enzyme activity dosage was reduced (
<xref rid="t1001" ref-type="table">Table 1</xref>
) and the genetic test (Sanger) revealed a pathogenic variant in the
<italic toggle="yes">GLA</italic>
gene (
<xref rid="t2001" ref-type="table">Table 2</xref>
), also identified in his mother.</p><p>
<fig position="float" id="f02001"><label>Figure 2</label><caption><title>&#x02013; Case 4: (G) Echocardiographic images demonstrating thickening of the papillary muscle, increased global LV thickness, and strain technique with involvement of the basal segment of the inferior, lateral, and inferolateral walls. Case 5: (H) Echocardiographic image showing thickening of the LV septal and lateral wall. Case 6: (I) Echocardiogram reveals LV thickening as well as increased end-diastolic diameter. Optical microscopy images, stained with Masson&#x02019;s trichrome, show areas of fibrosis (J) and hematoxylin eosin staining demonstrating extensive vacuolization of the cytoplasm of cardiomyocytes (K). (L) Coronal view of explanted heart with increased thickness of the entire myocardium.</title></caption><graphic xlink:href="0066-782X-abc-122-2-e20240535-gf02-en" position="float"/></fig>
</p></sec><sec><title>Case 05 &#x02013; Heart failure with preserved ejection fraction</title><p>A 68-year-old female patient, complained of dyspnea on exertion, which significantly limited her daily activities. She reported episodes of atypical precordial pain, unrelated to the effort, (
<xref rid="t1001" ref-type="table">Table 1</xref>
) with no other complaints. When asked about her family history, she said that her father had died at the age of 45 from an undetermined cause. The ECG showed a short PR interval, intraventricular conduction disturbance, and diffuse alterations in ventricular repolarization. The echocardiogram showed concentric ventricular hypertrophy of the LV, as well as increased thickness of the interventricular septum and lateral wall of 19 mm and 18 mm, respectively. The calculated LV-indexed mass was 320 g/m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>. The GLS was calculated and showed reduced values in the inferno-later-basal region (
<xref rid="f02001" ref-type="fig">Figure 2</xref>
). A genetic panel for evaluation of HCM genocopies showed the presence of a pathogenic variant in the
<italic toggle="yes">GLA</italic>
gene, confirming FD (
<xref rid="t2001" ref-type="table">Table 2</xref>
). Two of the patient&#x02019;s children underwent a family screening and the variant was identified in one of them.</p></sec><sec><title>Case 06 &#x02013; Heart failure with preserved ejection fraction</title><p>A 64-year-old male patient, with a history of HCM diagnosed 30 years ago, without other systemic symptoms (
<xref rid="t1001" ref-type="table">Table 1</xref>
), was admitted due to decompensated heart failure, profile C. Family history included a brother also diagnosed with HCM. Despite optimized treatment and cardiac resynchronization therapy performed three years earlier, the echocardiogram revealed an LV ejection fraction of 29% and ventricular hypertrophy with septal and lateral wall thicknesses of 17 mm (
<xref rid="f02001" ref-type="fig">Figure 2</xref>
). Due to being refractory to inotropic withdrawal, the patient was considered to be in the terminal phase of the disease and underwent a successful heart transplant.</p><p>Histopathological analysis of the explanted specimen (
<xref rid="f02001" ref-type="fig">Figure 2</xref>
) and a genetic panel (
<xref rid="t2001" ref-type="table">Table 2</xref>
) revealed a pathogenic variant in the
<italic toggle="yes">GLA</italic>
gene, with reduced levels of alpha-galactosidase enzyme activity. His brother was also sequenced for the same gene, and the same variant was found, of maternal origin.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>FD is an X-linked genetic condition that manifests differently in men and women. There are two main phenotypes: the classic, more common in men, characterized by the total loss of &#x003b1;-GalA enzyme function, resulting in multisystemic symptoms; and the non-classical, with late-onset variants that leads to a slower progression of the disease, usually affecting only the heart or kidneys.<sup>
<xref rid="B2" ref-type="bibr">2</xref>
,
<xref rid="B3" ref-type="bibr">3</xref>
</sup>New studies have shown the tendency for loss-of-function variants to generate a phenotype with greatly reduced enzymatic activity and a classic clinical condition, while missense variants are associated with late-onset phenotypes.<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>In the series described, three patients had variants that resulted in an early stop codon, but only case 4 evolved as described in the literature.</p><p>Not only the genetic variant, but lyso-Gb3, the deacetylated form of Gb3, is a marker of FD strongly associated with its phenotype. Its value tends to be high in patients with the classic form and lower in the non-classical form.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup></p><p>Male patients with late-onset FD have higher residual &#x003b1;-Gal A activity compared with classic FD, although still well below normal values.<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>In heterozygous women, &#x003b1;-Gal A activity may be normal or slightly deficient, often with asymptomatic clinical progression, which discourages serum measurement of this marker in this population, with the diagnosis being conditioned to genotype confirmation. In heterozygous women, the healthy X chromosome can be inactivated, with the one containing the variant being the one that predominates, generating severe symptoms in the classical clinical presentation of the disease. This genetic expression occurs randomly in each cell of the organism.<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup></p><p>Typical manifestations of FD, such as angiokeratomas and cornea verticillata, are less frequent, being more common in classical phenotypes. Adult patients with structural changes in the myocardium, progressive increase in myocardial thickening over time, conduction disorders, chronic kidney disease, and neurological symptoms, especially acroparesthesias and/or hypohidrosis, should be actively investigated for FD, as well as their family members.</p><p>The typical cardiac manifestation of FD is concentric left ventricular hypertrophy, common from the third decade of life onwards. This hypertrophy can be confused with other conditions, such as HCM and cardiac amyloidosis.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>Studies indicate that FD is present in 0.5 to 3% of the cases diagnosed as HCM.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup>In the case series presented, two patients had the diagnosis of FD erroneously attributed to HCM, resulting in a delay in ERT and, in one case, the need for heart transplantation.</p><p>On the ECG, changes such as reduced PR interval and increased prevalence of AF are indicative of FD. Echocardiography is key for the diagnosis and monitoring of Fabry cardiomyopathy, revealing, among other findings, thickening of the ventricular wall and diastolic dysfunction.<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup></p><p>CMRI is also useful, highlighting fibrosis in the inferolateral basal segments and reduced T1 map values, which may be early indicators of FD.</p><p>Specific treatment consists of ERT to replace the missing enzyme, consequently preventing the accumulation of Gb3. In Brazil, we have alpha-galsidase and beta-galsidase, both administered intravenously every two weeks. More recently, a new therapy has been proposed, chaperones. These agents have emerged to increase the therapeutic toolkit in the treatment of FD. However, this class has only demonstrated efficacy in specific subtypes of pathogenic variants, requiring in vitro validation of the medication for the patient&#x02019;s specific variant before its application. Chaperones act by maintaining the stability of the dysfunctional protein, assisting in its correct folding and, consequently, preserving its activity.<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup></p><p>Finally, a detailed clinical investigation, in addition to a genetic evaluation conducted by an experienced professional, is crucial for the diagnosis of FD. The ongoing training of cardiologists is essential to increase recognition of the disease and enable early interventions, which can slow disease progression and prevent serious complications, ensuring a better prognosis for patients.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Study association:</bold> This study is not associated with any thesis or dissertation work.</p></fn><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This study was approved by the Ethics Committee of the Associa&#x000e7;&#x000e3;o Lar S&#x000e3;o Francisco de Assis da Provid&#x000ea;ncia de Deus under the protocol number 63892722.1.0000.5514. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.</p></fn><fn fn-type="financial-disclosure"><p><bold>Sources of funding:</bold> There were no external funding sources for this study.</p></fn></fn-group></back></sub-article></article>